Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Inclusion Criteria: * Patients 18 years of age or older. * Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate * Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna (nilotinib) 300-400 mg twice daily * ECOG Performance status 0, 1, or 2 * Adequate end organ function, defined as: * Total bilirubin \< 1.5 xULN * SGOT and SGPT \<2.5 x ULN * Creatinine \< 1.5 x ULN * ANC \> 1.5 * Platelets \> 100,000 * Female patients of child bearing potential must have a negative urine or serum pregnancy test at screening. * Patient is able to read and speak English * Patient is willing and able to use a cell phone * Written, voluntary informed consent Exclusion Criteria: * Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent